BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/19/2026 12:16:38 PM | Browse: 7 | Download: 2
Publication Name World Journal of Gastroenterology
Manuscript ID 126723
DOI 10.3748/wjg.126723
Country China
Category Oncology
Manuscript Type Retrospective Cohort Study
Article Title Enterochromaffin-like cell hyperplasia grade as a surveillance marker in type 1 gastric neuroendocrine tumors
Manuscript Source Unsolicited Manuscript
All Author List Ru-Ao Chen, Yan-Fen Shi, Yu-Yang Wang, Yan-Mei Li, Wen-Juan Guo, Fu-Huan Yu, Ying-Ying Chen, Jie Luo, Huang-Ying Tan and Chao Deng
Funding Agency and Grant Number
Funding Agency Grant Number
the National High Level Hospital Clinical Research Funding 2025-NHLHCRF-PY-11
Corresponding Author Huang-Ying Tan, PhD, Professor, Department of Integrative Oncology, China-Japan Friendship Hospital, No. 2 Yinghuayuan East Street, Chaoyang District, Beijing 100029, China. tanhuangying@zryhyy.com.cn
Key Words Type 1 gastric neuroendocrine tumors; Enterochromaffin-like cell hyperplasia; Disease progression; Traditional Chinese medicine; Prognostic model; Autoimmune thyroid disease; Retrospective cohort study
Core Tip This retrospective cohort study of 107 patients with type 1 gastric neuroendocrine tumors found that enterochromaffin-like (ECL) cell hyperplasia grade is closely associated with tumor burden, serving as a surveillance marker rather than an independent prognostic factor. A four-variable nomogram incorporating neuroendocrine tumors number ≥ 3, autoimmune thyroid disease, anemia, and intrinsic factor antibody positivity stratified patients into three risk groups. Autoimmune thyroid disease was protective, whereas traditional Chinese medicine use showed a favorable but preliminary association. These findings support ECL-guided surveillance with risk-stratified management, pending external validation.
Citation Chen RA, Shi YF, Wang YY, Li YM, Guo WJ, Yu FH, Chen YY, Luo J, Tan HY, Deng C. Enterochromaffin-like cell hyperplasia grade as a surveillance marker in type 1 gastric neuroendocrine tumors. World J Gastroenterol 2026; In press
PDF 126723-in-press.pdf
Received
2026-08-12 03:46
Peer-Review Started
2026-08-12 03:47
First Decision by Editorial Office Director
Return for Revision
2026-08-25 01:47
Revised
2026-09-16 17:43
Publication Fee Transferred
2026-09-29 07:38
Editorial Processing by Scientific Editor
2026-11-19 06:49
Final Academic Decision by Editor-in-Chief
Publication Technical Verification by Editorial Office Director
2026-11-19 12:16
Articles in Press
2026-11-19 12:16
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright © The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com